Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and developing chemotherapy for CLL.

Emili Montserrat1

  • 1Postgraduate School of Hematology, Hospital Clinic, University of Barcelona, Villarroel, Spain. emili@medicina.ub.es

Medical Oncology (Northwood, London, England)
|August 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

American journal of hematology·2023
Same author

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

British journal of haematology·2023
Same author

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

Journal of hematology & oncology·2022
Same author

mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.

European journal of haematology·2021
Same author

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Leukemia·2021
Same author

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.

Frontiers in oncology·2021
Same journal

Phytochemicals remodel antitumor immunity via the "microbiota-metabolite-receptor" axis: focus on colorectal cancer and immunotherapy.

Medical oncology (Northwood, London, England)·2026
Same journal

Combinatorial cancer therapy mediated by hydroxyapatite nanoparticles: a comprehensive review.

Medical oncology (Northwood, London, England)·2026
Same journal

IFITM3 promotes an M2-like tumor-supportive microenvironment in acute myeloid leukemia.

Medical oncology (Northwood, London, England)·2026
Same journal

Liposomal honokiol attenuates dimethylhydrazine-induced colon carcinogenesis in rats through modulation of oxidative stress, inflammation, apoptosis, autophagy, and lipid metabolism pathways.

Medical oncology (Northwood, London, England)·2026
Same journal

Identification of a lncRNA prognostic signature reveals that SNAI3-AS1 cooperates with erastin to reshape macrophage polarization in glioma.

Medical oncology (Northwood, London, England)·2026
Same journal

Effects of Astragalus membranaceus injection at Zusanli (ST36) acupoint on lung cancer with COPD.

Medical oncology (Northwood, London, England)·2026
See all related articles

Treatment for chronic lymphocytic leukemia (CLL) is shifting from palliative care to active intervention for progressive disease. Advances like purine analogs, especially fludarabine, and combination therapies are significantly improving patient response rates and outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment historically focused on palliative care.
  • A paradigm shift is occurring towards active intervention for progressive CLL.
  • Recent advancements offer new therapeutic strategies.

Purpose of the Study:

  • To review the evolving treatment landscape for chronic lymphocytic leukemia.
  • To highlight the impact of novel therapeutic agents and combinations.
  • To discuss improvements in response rates and duration of response.

Main Methods:

  • Review of recent clinical studies and treatment guidelines for CLL.
  • Analysis of efficacy data for purine analogs and combination therapies.
  • Evaluation of treatment outcomes in previously untreated and progressive disease cohorts.

Related Experiment Videos

Main Results:

  • Purine analogs, particularly fludarabine, have markedly improved response rates in untreated CLL.
  • Combination chemotherapies, including fludarabine with alkylating agents or monoclonal antibodies, further enhance treatment efficacy.
  • Improvements observed in the frequency, quality, and duration of responses.

Conclusions:

  • The treatment of chronic lymphocytic leukemia is increasingly focused on achieving durable responses and improved survival.
  • Fludarabine-based regimens represent a significant advancement in CLL therapy.
  • Combination therapies hold promise for optimizing outcomes in CLL patients.